BCRX · BioCryst Pharma
AI read · Good for BCRX
The AI's read
The results point to stronger demand for BioCryst’s main medicine, and the new child-friendly forms could reach more patients. The company-reported operating profit measure also rose. Some of the higher revenue forecast comes from licensing income and RAPIVAB orders, not just medicine sales. A fully enrolled trial could bring another medicine, but its main results are not due until next year.